Text Size

Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma

Klimko P.G., Sharif N.A.


  • 2019
  • British Journal of Pharmacology
View publication
  • Therapeutic Area

    Glaucoma

  • Technology

    Pharmacology

  • Affiliations

    Novartis Pharmaceuticals Corporation, Fort Worth, TX 76134, United States; Santen Incorporated, Emeryville, CA 94608, United States

Related Publications

Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.


Müller glia derived EVs promote neurite recovery of an enriched population of retinal ganglion like cells derived from hESC retinal organoids after damage

Eastlake K, Lamb WDB, Tracey-White D, Shibagaki K, Khaw PT, Jayaram H, Limb GA


An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022